Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Leases: 2019-2024

Historic Current Leases for Cytokinetics (CYTK) over the last 6 years, with Dec 2024 value amounting to $19.0 million.

  • Cytokinetics' Current Leases rose 9.50% to $20.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 9.50%. This contributed to the annual value of $19.0 million for FY2024, which is 6.08% up from last year.
  • Per Cytokinetics' latest filing, its Current Leases stood at $19.0 million for FY2024, which was up 6.08% from $17.9 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Current Leases ranged from a high of $19.0 million in FY2024 and a low of $2.8 million during FY2020.
  • Moreover, its 3-year median value for Current Leases was $17.9 million (2023), whereas its average is $16.6 million.
  • Per our database at Business Quant, Cytokinetics' Current Leases plummeted by 39.67% in 2020 and then skyrocketed by 433.68% in 2021.
  • Over the past 5 years, Cytokinetics' Current Leases (Yearly) stood at $2.8 million in 2020, then soared by 433.68% to $14.9 million in 2021, then declined by 13.68% to $12.8 million in 2022, then spiked by 39.46% to $17.9 million in 2023, then rose by 6.08% to $19.0 million in 2024.